The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Rapamycin Markedly Slows Disease Progression in a Rat Model of Polycystic Kidney Disease
Abstract
Increased tubular epithelial cell proliferation is a prerequisite for cyst formation and expansion in polycystic kidney disease (PKD). Rapamycin is a potent antiproliferative agent. The aim of the present study was to determine the effect of rapamycin on tubular cell proliferation, cyst formation, and renal failure in the Han:SPRD rat model of PKD. Heterozygous (Cy/+) and littermate control (+/+) male rats were weaned at 3 wk of age and then treated with rapamycin 0.2 mg/kg per d intraperitoneally or vehicle (ethanol) for 5 wk. Vehicle-treated Cy/+ rats had a more than doubling of kidney size compared with +/+ rats. Rapamycin reduced the kidney enlargement by 65%. Rapamycin significantly reduced the cyst volume density in Cy/+ rats by >40%. Blood urea nitrogen was 59% increased in vehicle-treated Cy/+ rats compared with +/+ rats. Rapamycin reduced the blood urea nitrogen to normal in Cy/+ rats. The number of proliferating cell nuclear antigen (PCNA)-positive cells per noncystic tubule was eightfold increased in vehicle-treated Cy/+ compared with +/+ rats. Rapamycin significantly reduced the number of PCNA-positive cells in noncystic tubules of Cy/+ rats. In addition, the number of PCNA-positive cells per cyst in Cy/+ rats was significantly reduced by rapamycin. In summary, in a rat model of PKD, rapamycin treatment (1) decreases proliferation in cystic and noncystic tubules, (2) markedly inhibits renal enlargement and cystogenesis, and (3) prevents the loss of kidney function.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ravikumar, B., Vacher, C., Berger, Z., Davies, J. E., Luo, S., Oroz, L. G., Scaravilli, F., Easton, D. F., Duden, R., O'Kane, C. J., et al. (2004) · Nature Genetics · doi:10.1038/ng1362 · Cited by 2,347
TOR, a Central Controller of Cell Growth
Schmelzle, T., & Hall, M. N. (2000) · Cell · doi:10.1016/s0092-8674(00)00117-3 · Cited by 1,924
Fingar, D. C., & Blenis, J. (2004) · Oncogene · doi:10.1038/sj.onc.1207542 · Cited by 1,247
Wilson, P. D. (2004) · New England Journal of Medicine · doi:10.1056/nejmra022161 · Cited by 916
Targeting mTOR signaling for cancer therapy
Huang, S. (2003) · Current Opinion in Pharmacology · doi:10.1016/s1471-4892(03)00071-7 · Cited by 436
Lieberthal, W., Fuhro, R., Andry, C. C., Rennke, H., Abernathy, V. E., Koh, J. S., Valeri, R., & Levine, J. S. (2001) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.2001.281.4.f693 · Cited by 270
Autosomal-dominant polycystic kidney disease in the rat
Cowley, B. D., Gudapaty, S., Kraybill, A. L., Barash, B. D., Harding, M. A., Calvet, J. P., & Gattone, V. H. (1993) · Kidney International · doi:10.1038/ki.1993.79 · Cited by 222
c-myc as an inducer of polycystic kidney disease in transgenic mice
Trudel, M., D'Agati, V., & Costantini, F. (1991) · Kidney International · doi:10.1038/ki.1991.80 · Cited by 210
EGF receptor tyrosine kinase inhibition attenuates the development of PKD in Han:SPRD rats
Torres, V. E., Sweeney, W. E., Wang, X., Qian, Q., Harris, P. C., Frost, P., & Avner, E. D. (2003) · Kidney International · doi:10.1046/j.1523-1755.2003.00256.x · Cited by 135
Characterization of the Han:SPRD rat model for hereditary polycystic kidney disease
Schäfer, K., Gretz, N., Bäder, M., Oberbäumer, I., Eckardt, K., Kriz, W., & Bachmann, S. (1994) · Kidney International · doi:10.1038/ki.1994.253 · Cited by 127
Cited by
Autosomal dominant polycystic kidney disease
Torres, V. E., Harris, P. C., & Pirson, Y. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60601-1 · Cited by 1,550
When cilia go bad: cilia defects and ciliopathies
Fliegauf, M., Benzing, T., & Omran, H. (2007) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2278 · Cited by 1,257
Everolimus in Patients with Autosomal Dominant Polycystic Kidney Disease
Walz, G., Budde, K., Mannaa, M., Nürnberger, J., Wanner, C., Sommerer, C., Kunzendorf, U., Banas, B., Hörl, W. H., Obermüller, N., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003491 · Cited by 587
Sirolimus and Kidney Growth in Autosomal Dominant Polycystic Kidney Disease
Serra, A. L., Poster, D., Kistler, A. D., Krauer, F., Raina, S., Young, J., Rentsch, K. M., Spanaus, K. S., Senn, O., Kristanto, P., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0907419 · Cited by 571
ACG Clinical Guideline: The Diagnosis and Management of Focal Liver Lesions
Marrero, J. A., Ahn, J., & Reddy, R. K. (2014) · American Journal of Gastroenterology · doi:10.1038/ajg.2014.213 · Cited by 477
Metadata
- Authors
- Tao, Y., Kim, J., Schrier, R. W., & Edelstein, C. L.
- Venue
- Journal of the American Society of Nephrology
- Published
- 2005-01
- Volume
- 16
- Issue
- 1
- Pages
- 46-51
- ISSN
- 1046-6673 (ISSN-L)
- OpenAlex
- W2154820433
- Cited by
- 391
- References
- 16
- FWCI
- 12.12
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Rapamycin Markedly Slows Disease Progression in a Rat Model of Polycystic Kidney Disease. https://app.cochat.ai/papers/10.1681/asn.2004080660
- The paper
- Tao, Y., Kim, J., Schrier, R. W., & Edelstein, C. L. (2005). Rapamycin Markedly Slows Disease Progression in a Rat Model of Polycystic Kidney Disease. Journal of the American Society of Nephrology. https://doi.org/10.1681/asn.2004080660
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.